Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEST RT: Durvalumab + Chemo + RT in ES-SCLC
NCT05796089Phase 2Active, not recruiting
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jan 2022
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by Trans-Tasman Radiation Oncology Group. Started Jan 2022; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05796089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796089.